mefenamic acid has been researched along with probenecid in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Fujiwara, R; Koga, T; Nakajima, M; Yokoi, T | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Boa, AN; Chandrabalan, A; McPhillie, MJ; Morice, AH; Sadofsky, LR | 1 |
| Kalgutkar, AS | 1 |
| Bluestone, R; Kippen, I; Klinenberg, JR; Whitehouse, MW | 1 |
| Abe, F; Fujimoto, Y; Fukuda, M; Hasegawa, T; Kitaichi, K; Morishima, T; Takagi, K | 1 |
| Chen, J; Hanna, I; Koo, P; Majumdar, T; Mendonza, A; Meyers, D; Neelakantham, S; Rebello, S; Sunkara, G; Zhu, B | 1 |
2 review(s) available for mefenamic acid and probenecid
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for mefenamic acid and probenecid
| Article | Year |
|---|---|
Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid.
Topics: Acetates; Adolescent; Adult; Aminopyridines; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Interactions; Female; Glucuronosyltransferase; Healthy Volunteers; Humans; Male; Mefenamic Acid; Middle Aged; Probenecid; Young Adult | 2016 |
13 other study(ies) available for mefenamic acid and probenecid
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Comet Assay; DNA Damage; Glucuronides; Glucuronosyltransferase; HEK293 Cells; Hepatocytes; Humans; Kidney | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
Topics: Animals; Calcium Signaling; Cinnamates; Guinea Pigs; HEK293 Cells; Humans; Male; Molecular Docking Simulation; ortho-Aminobenzoates; Structure-Activity Relationship; TRPA1 Cation Channel | 2019 |
Designing around Structural Alerts in Drug Discovery.
Topics: Drug Design; Drug Development; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Humans; Molecular Structure; Pharmaceutical Preparations; Structure-Activity Relationship | 2020 |
Effect of some uricosuric and anti-inflammatory drugs on the binding of uric acid to human serum albumin in vitro.
Topics: Allopurinol; Anti-Inflammatory Agents; Aspirin; Binding Sites; Caprylates; Colchicine; Dialysis; Fluorescence; Humans; In Vitro Techniques; Indomethacin; Mefenamic Acid; Phenylbutazone; Probenecid; Protein Binding; Serum Albumin; Sodium Salicylate; Sulfinpyrazone; Uric Acid; Uricosuric Agents | 1970 |
Altered brain penetration of diclofenac and mefenamic acid, but not acetaminophen, in Shiga-like toxin II-treated mice.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Blood-Brain Barrier; Brain; Cyclooxygenase Inhibitors; Cytokines; Diclofenac; Male; Mefenamic Acid; Mice; Organic Anion Transporters, Sodium-Independent; Probenecid; Protein Binding; Shiga Toxin 2 | 2005 |